menu
    • menu
    [{"orgOrder":0,"company":"MPM Capital","sponsor":"Cullinan Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"VK-2019","moa":"EBNA-1","graph1":"Oncology","graph2":"Phase I","graph3":"MPM Capital","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"MPM Capital \/ MPM Capital","highestDevelopmentStatusID":"6","companyTruncated":"MPM Capital \/ MPM Capital"},{"orgOrder":0,"company":"MPM Capital","sponsor":"BioIntervene","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"BIO-205","moa":"A3AR","graph1":"Neurology","graph2":"Preclinical","graph3":"MPM Capital","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"MPM Capital \/ MPM Capital","highestDevelopmentStatusID":"4","companyTruncated":"MPM Capital \/ MPM Capital"},{"orgOrder":0,"company":"MPM Capital","sponsor":"ReCode Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"MPM Capital","amount2":0.080000000000000002,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Aerosol","sponsorNew":"MPM Capital \/ MPM Capital","highestDevelopmentStatusID":"4","companyTruncated":"MPM Capital \/ MPM Capital"},{"orgOrder":0,"company":"MPM Capital","sponsor":"Umoja Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series A Financing","leadProduct":"VivoCAR-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"MPM Capital","amount2":0.050000000000000003,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"MPM Capital \/ MPM Capital","highestDevelopmentStatusID":"4","companyTruncated":"MPM Capital \/ MPM Capital"}]

    Find Clinical Drug Pipeline Developments & Deals by MPM Capital

    Menu

    MPM Capital

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            MPM Capital

                            U.S.A arrow
                            Vitafoods
                            Not Confirmed

                            MPM Capital

                            U.S.A arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VivoCAR-T Cell

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Umoja Biopharma

                            Deal Size : $53.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Umoja Biopharma Launches with $53M Series A Financing to Develop Fully Integrated, Scalable, In Vivo Immunothe...

                            Details : The Series A financing will enable Umoja to advance its platform and therapeutic programs to early clinical development. Umoja’s platform incorporates three core components: the VivoVec delivery platform, RACR/CAR payload architecture, and the TumorTag...

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            November 18, 2020

                            Lead Product(s) : VivoCAR-T Cell

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Umoja Biopharma

                            Deal Size : $53.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            MPM Capital

                            U.S.A arrow
                            Vitafoods
                            Not Confirmed

                            MPM Capital

                            U.S.A arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BIO-205

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : BioIntervene

                            Deal Size : $30.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            MPM backs new biotech in the hunt for non-opioid painkiller

                            Details : The financing will be used to advance the company’s lead program, BIO-205, through human proof-of-concept studies in neuropathic pain as well as to advance its portfolio of A3AR agonists.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            July 01, 2020

                            Lead Product(s) : BIO-205

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : BioIntervene

                            Deal Size : $30.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            MPM Capital

                            U.S.A arrow
                            Vitafoods
                            Not Confirmed

                            MPM Capital

                            U.S.A arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VK-2019

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Cullinan Therapeutics

                            Deal Size : $98.5 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Cullinan Oncology Completes $98.5 Million Series B Financing

                            Details : Funds raised by the financing will be used to support ongoing clinical trials across its small molecule and biologics portfolio.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            April 06, 2020

                            Lead Product(s) : VK-2019

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Cullinan Therapeutics

                            Deal Size : $98.5 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            MPM Capital

                            U.S.A arrow
                            Vitafoods
                            Not Confirmed

                            MPM Capital

                            U.S.A arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Study Phase : Undisclosed

                            Recipient : ReCode Therapeutics

                            Deal Size : $80.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            ReCode Therapeutics Raises $80 Million in Oversubscribed Series A Financing

                            Details : ReCode will use the proceeds to continue the preclinical development of its lead programs in primary ciliary dyskinesia and cystic fibrosis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 26, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Undisclosed

                            Recipient : ReCode Therapeutics

                            Deal Size : $80.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth